drug
PADCEV
updated 6mo agoby Astellas Pharma Inc
community read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying PADCEV
News(10)
- Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera assetWith 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.biospace · 4d ago
- Pfizer flat in Q3 despite 32% growth for new and acquired productsSales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.biospace · 13d ago
- Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdictWith companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…biospace · 14d ago
- #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancerMADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli L…endpoints · 23d ago
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.fiercebiotech · 3mo ago
- Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launchSome analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.biopharma_dive · 3mo ago
- Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructureThe additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major…biospace · 3mo ago
- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…fiercebiotech · 3mo ago
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.biopharma_dive · 4mo ago
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…endpoints · 4mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that